VERAXA Biotech pipeline update
Analysis based on 7 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The update reinforces VERAXA's focus on its differentiated BiTAC platform, which could attract partnering interest and funding. Positive sentiment in the biotech sector for T-cell engagers and ADCs may support the company's stock.
On July 6, 2026, VERAXA Biotech AG AG (Nasdaq: VRXA) provided a company and pipeline update, highlighting progress in the first half of 2026. The company reported advancing its proprietary BiTAC platform, which includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to finance development. The goal is to have lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028. Executives noted strong industry interest in T-cell engager and ADC technologies, reinforced by discussions at the BIO International Convention and other events. The company also highlighted a strategic partnership with OmniAb, Inc. for a bsADC program. VERAXA was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL).
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard